Featured Articles

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

By May 12, 2020May 20th, 2020No Comments

Dermatology News

Featured Article

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

Read Article Now

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

A study recently published in the JDD reveals phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis vulgaris

Phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis, according to Mark S. Nestor, M.D., Ph.D., in a study recently published in the Journal of Drugs in Dermatology.
Current options for treating psoriasis include systemic and topical agents: systemic treatment options may involve immune inhibitors, and/or immune modulators. For moderate to severe cases, biologic agents may be used.
Topical agents may be comprised of ointments, medicated baths, and phototherapy.

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

“Additionally,” he added, “laser has largely taken over for individual and spot treatment of specific areas because you don’t have the same issue of systemic problems with burning.”

In the study, “Randomized, Investigator-Blinded Study to Compare the Efficacy and Tolerance of a 650-microsecond, 1064-nm YAG Laser to a 308-nm Excimer Laser for the Treatment of Mild to Moderate Psoriasis Vulgaris,” co-authored by Dr. Nestor, Daniel Fischer DO MS,a and David Arnold DOa eligible subjects enrolled in a randomized, investigator-blinded study.

Psoriatic plaques on one side of the body were treated with the 650-microsecond laser and plaques on the other side were treated with the 308-nm excimer laser. Study subjects received up to 15 treatments, twice weekly, or fewer if full clearance was achieved. Efficacy and tolerance were evaluated by the mPASI scores and local skin reactions, respectively.

Both devices showed efficacy in treating psoriatic plaques. Differences between the two devices were not significant for redness, thickness, scaliness, mPASI scores for arms and legs, and overall mPASI scores for the treated psoriatic plaques on each side of the body. The investigator-assessed scores for erosion/ulceration, vesicles, erythema, scaling, edema, and atrophy were low and identical for both sides of the body.

“There is potential for utilizing this therapy much more in the future, especially in areas such as the palms and soles, where excimer appears to be less effective,” Dr. Nestor said.

Read Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Article About Social Media as a Catalyst for Health Education and Early Diagnosis of Hidradenitis Suppurativa. Image also from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas. It features a lighter skin tone patient who has HS under arm.Featured ArticlesLatest NewsThe Latest
June 6, 2025

Social Media as a Catalyst for Health Education and Early Diagnosis of Hidradenitis Suppurativa

Has TikTok Helped Your Patients Recognize Hidradenitis Suppurativa Sooner? You might have heard it from your own patients: “I saw a video on TikTok and realized I might have HS.”…
Journal of Drugs in Dermatology JDD Article About Exploring the Gut Microbiome’s Role in Drug-Induced Photosensitivity: A Need for Deeper InvestigationFeatured ArticlesLatest NewsThe Latest
June 5, 2025

Exploring the Gut Microbiome’s Role in Drug-Induced Photosensitivity: A Need for Deeper Investigation

Is Your Patient’s Gut Making Their Skin More Sensitive to the Sun? Drug-induced photosensitivity is nothing new, but could the gut microbiome be influencing how severely patients react to sunlight?…
Journal of Drugs in Dermatology JDD Article About Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and IsotretinoinAcneFeatured ArticlesLatest NewsThe Latest
June 3, 2025

Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin

GLP-1RAs and Isotretinoin: A Risky Combination? Recent reports on dermatologic side effects of GLP-1 receptor agonists (GLP-1RAs) have prompted a closer look at how these drugs interact with other treatments,…

Leave a Reply